Ole Isacson Net Worth

Ole Isacson biography

Dr. Ole Isacson M.D., Ph.D. serves as Independent Director of the Company. He has served as a member of our Board of Directors since we commenced operations as an independent company in April 2019. Dr. Isacson has been professor of neurology and neuroscience at Harvard Medical School since 2002. Prior to his current role, Dr. Isacson served in a number of academic roles at Harvard Medical School. Since its founding in 2005, Dr. Isacson has been principal faculty of the Harvard Stem Cell Institute and is the founding director of the Neuroregeneration Institute at McLean Hospital, where he has served as a director since 2010. From September 2016 to May 2017, Dr. Isacson was the chief scientific officer and senior vice president for Pfizer Inc.’s Neuroscience and Pain Worldwide R&D division. Dr. Isacson received his Medical Bachelor and Doctor of Medicine degrees from the University of Lund in Sweden.

What is the salary of Ole Isacson?

As the Independent Director of Cyclerion Therapeutics, the total compensation of Ole Isacson at Cyclerion Therapeutics is $141,253. There are 8 executives at Cyclerion Therapeutics getting paid more, with Andreas Busch having the highest compensation of $3,251,110.

How old is Ole Isacson?

Ole Isacson is 60, he's been the Independent Director of Cyclerion Therapeutics since 2019. There are 6 older and 8 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.

What's Ole Isacson's mailing address?

Ole's mailing address filed with the SEC is C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Cyclerion Therapeutics

Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie, and Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.

What does Cyclerion Therapeutics do?

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics executives and stock owners

Cyclerion Therapeutics executives and other stock owners filed with the SEC include:

• Andreas Busch,
  Chief Innovation Officer, Head of the Innovation Center
• Dr. Andreas Busch Ph.D.,
  Chief Scientific Officer
• Mark Currie,
  President, Chief Scientific Officer
• Marsha Fanucci,
  Independent Chairman of the Board
• Terrance McGuire,
  Independent Director
• Amy Schulman,
  Independent Director
• George Conrades,
  Independent Director
• Stephanie Lovell,
  Independent Director
• Ole Isacson,
  Independent Director
• Kevin Churchwell,
  Independent Director
• Michael Mendelsohn,
  Independent Director
• Peter Hecht,
  Chief Executive Officer, Director
• Dr. Peter M. Hecht Ph.D.,
  CEO, Interim CFO, Principal Accounting Officer & Director
• William Huyett,
  Chief Financial Officer
• Jennifer Chickering,
  Sr. Director of Clinical Strategy
• Christopher Winrow,
  Sr. Director of Clinical Devel. & Neuroscience Program Lead
• Jessica Rennekamp,
  Associate Director of Corp. Communications
• Dr. Todd Milne Ph.D.,
  VP of Corp. Devel.
• Cheryl Gault,
  Chief Operating Officer
• Anjeza Gjino,
  CFO & Corp. Sec. (Maternity Leave of Absence)
• Regina Margaret Graul,
  See Remarks
• Path Capital Lp Greenspan D...,
  
• Christopher I Wright,
  Chief Medical Officer
• Anjeza Gjino,
  Chief Financial Officer
• Errol B Desouza,
  
• Pharmaceuticals Inc Ironwood,
  10% owner
• Cheryl Gault,
  Chief Operating Officer
• Steven Hyman,